40,914 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Purchased by Graham Capital Management L.P.

Graham Capital Management L.P. bought a new stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 40,914 shares of the company’s stock, valued at approximately $245,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ADPT. KBC Group NV bought a new stake in shares of Adaptive Biotechnologies during the fourth quarter valued at approximately $50,000. Cibc World Markets Corp bought a new position in Adaptive Biotechnologies in the 4th quarter worth approximately $65,000. Bridgefront Capital LLC acquired a new stake in Adaptive Biotechnologies in the 4th quarter valued at approximately $80,000. Amundi raised its stake in Adaptive Biotechnologies by 41.2% during the 4th quarter. Amundi now owns 15,532 shares of the company’s stock valued at $93,000 after acquiring an additional 4,531 shares in the last quarter. Finally, Proficio Capital Partners LLC acquired a new position in Adaptive Biotechnologies during the 4th quarter worth $93,000. 99.17% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Chad M. Robins sold 211,160 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $8.50, for a total transaction of $1,794,860.00. Following the completion of the sale, the chief executive officer now directly owns 2,576,701 shares of the company’s stock, valued at $21,901,958.50. This trade represents a 7.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Francis Lo sold 20,875 shares of the business’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $6.99, for a total value of $145,916.25. Following the sale, the insider now directly owns 332,846 shares in the company, valued at $2,326,593.54. This trade represents a 5.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 667,092 shares of company stock worth $5,198,980. Corporate insiders own 6.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ADPT. The Goldman Sachs Group raised their price target on Adaptive Biotechnologies from $9.00 to $10.00 and gave the company a “buy” rating in a report on Friday, May 2nd. Piper Sandler restated an “overweight” rating and set a $13.00 price target (up from $11.00) on shares of Adaptive Biotechnologies in a research report on Tuesday, May 6th. Morgan Stanley upped their price target on shares of Adaptive Biotechnologies from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Monday, May 5th. Finally, Scotiabank raised their price objective on shares of Adaptive Biotechnologies from $10.00 to $12.00 and gave the company a “sector outperform” rating in a research note on Thursday, February 13th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $9.83.

Adaptive Biotechnologies Stock Up 1.6%

Shares of ADPT stock opened at $9.05 on Monday. The stock has a 50-day simple moving average of $8.03 and a 200 day simple moving average of $7.23. The stock has a market capitalization of $1.37 billion, a P/E ratio of -8.30 and a beta of 1.75. Adaptive Biotechnologies Co. has a fifty-two week low of $2.99 and a fifty-two week high of $10.28.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.08. Adaptive Biotechnologies had a negative net margin of 89.12% and a negative return on equity of 64.65%. The company had revenue of $52.44 million during the quarter, compared to analyst estimates of $42.13 million. During the same quarter last year, the firm posted ($0.33) EPS. The business’s revenue for the quarter was up 25.2% on a year-over-year basis. On average, sell-side analysts anticipate that Adaptive Biotechnologies Co. will post -0.92 earnings per share for the current year.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.